Bonesupport stock recovers following market volatility over preclinical study

Bonesupport shares rebounded after a Friday sell-off triggered by a preclinical study on mice regarding the antibiotic release profile of its Cerament product. The market reaction appears to have been an overcorrection to preliminary research, as the company's valuation stabilized following the initial dip.